EAN 2024 | Novel agents being explored for the treatment of CIDP

Luis Querol Gutierrez, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, outlines recent advancements in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP), including promising results from a Phase II trial of riliprubart (NCT04658472) and the FDA approval of efgartigimod. He also discusses ongoing trials for other agents in the same class and the potential of immunoglobulin analogs and complement inhibitors, highlighting a transformative period for therapeutic options in this field. This interview took place at the European Academy of Neurology (EAN) Annual Meeting 2024 in Helsinki, Finland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.